Astena Holdings Co Ltd
Astena Holdings Co Ltd maintains a debt-to-equity ratio of 0.84, indicating a moderate reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.24, suggesting it can cover its short-term liabilities but with limited buffer. The company's cash and equivalents amount to 10,190,000,000 JPY, which is less than its long-term debt of 22,649,000,000 JPY, resulting in a net cash position that is negative after subtracting total debt. In terms of profitability, Astena Holdings Co Ltd reports a return on equity (ROE) of 8.07% and a return on assets (ROA) of 2.9%. These figures are below the typical thresholds for strong performance in the pharmaceutical industry, indicating that the company is generating returns, but not at a level that would be considered exceptional. The operating income of 2,837,000,000 JPY and net income of 218,600,000 JPY further support the notion that the company is profitable, but not highly so. Astena Holdings Co Ltd operates through four business segments: Fine Chemicals, Medical, Health & Beauty Care (HBC) and Food, and Industrial Chemicals. The Fine Chemicals segment is engaged in the manufacture and sale of pharmaceutical raw materials and pharmaceuticals. The Medical segment is engaged in the manufacturing and sales of pharmaceutical products. The HBC and Food segment is engaged in the manufacture and sale of cosmetic raw materials, functional food raw materials, general use medicines, and related products, as well as cosmetics. The Industrial Chemicals segment manufactures and sells chemicals for electronic industries, surface treatment chemicals, chemical products, surface treatment chemical raw materials, and to printed circuit board and other manufacturing plants. The company's growth trajectory is reflected in its recent financial performance. The operating cash flow of 3,393,000,000 JPY and free cash flow of 696,000,000 JPY indicate that the company is generating positive cash flows from operations. However, the capital expenditure of -3,175,000,000 JPY suggests that the company is investing in its operations, which could be a sign of growth or expansion. The revenue of 62,744,000,000 JPY and gross profit of 21,867,000,000 JPY indicate that the company is generating significant revenue and profit, but the exact growth rate is not provided. The risk assessment for Astena Holdings Co Ltd indicates a medium liquidity risk and a low dilution risk. The key flags include the fact that the company's net cash is negative after subtracting total debt, which could be a concern for liquidity. The dilution risk is low, suggesting that the company is not expected to issue a significant amount of new shares in the near future. The company's capital structure and liquidity position are important factors to consider when assessing its financial health. Recent events related to Astena Holdings Co Ltd include the latest actual EPS of 54.23 JPY and the latest actual revenue of 62,744,000,000 JPY. These figures are based on analyst estimates and provide insight into the company's recent performance. The company's financial performance is in line with its reported revenue and net income, indicating that it is meeting or exceeding expectations.
Business. Astena Holdings Co Ltd operates in the pharmaceuticals and fine chemicals industry, generating revenue through the manufacture and sale of pharmaceutical raw materials, pharmaceutical products, cosmetic and food raw materials, and industrial chemicals.
Classification. Astena Holdings Co Ltd is classified under the Healthcare economic sector, Pharmaceuticals & Medical Research business sector, and Pharmaceuticals industry with a confidence level of 0.92.
- Astena Holdings Co Ltd has a moderate debt-to-equity ratio of 0.84, indicating a balanced capital structure.
- The company's return on equity of 8.07% and return on assets of 2.9% suggest it is profitable but not highly so.
- The company operates through four business segments, with a focus on pharmaceuticals, fine chemicals, and industrial chemicals.
- The company's liquidity position is characterized as medium, with a current ratio of 1.24.
- The company's net cash is negative after subtracting total debt, which could be a concern for liquidity.
- The company's recent financial performance, including an operating cash flow of 3,393,000,000 JPY and free cash flow of 696,000,000 JPY, indicates positive cash generation.
- --
- # RATIONALES
- Net cash is negative after subtracting total debt.